01276 恒瑞醫藥
HENGRUI PHARMA
HENGRUI PHARMA
| Listing Date | 2025/05/23 |
| Listing Price | 44.050 |
Subscription Result
- Subscription Rate454.85x
- Guarantee One Lot Size50 lot
- One Lot Success Rate10%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading innovative global pharmaceutical company rooted in China. The Group had a leading position among Chinese pharmaceutical companies, in terms of revenue from new molecular entity drugs in 2023 and the number of NME drug candidates in clinical or later stages of development as of May 5, 2025, according to Frost & Sullivan.
--
The Group strategically focus on comprehensive therapeutic areas, these mainly include: oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience.
--
As of May 5, 2025, the Group had over 110 commercialized drugs, including 19 NME drugs and four other innovative drugs. In addition, the Group had a pipeline of over 90 NME drug candidates and seven other innovative drug candidates in clinical or later stages of development.
--
The Group’s customers primarily consist of distributors of its pharmaceutical products in China and around the globe and international pharmaceutical companies to which it out-licensed certain rights with respect to its drugs and drug candidates. As of December 31, 2024, the Group’s distribution network comprised 597 distributors in over 30 provincial-level regions in China and for overseas markets.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 224.52M H shares |
| No. of International Offer Shares | 176.25M H shares |
| No. of HK Offer Shares | 48.27M H shares |
| Offer Price | $41.45 - $44.05 |
| Stock Code | 1276 |
| Sponsor(s) | Morgan Stanley Asia Limited, Citigroup Global Markets Asia Limited, Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, Citigroup Global Markets Asia Limited, Huatai Financial Holdings (Hong Kong) Limited, UBS AG Hong Kong Branch, BOCI Asia Limited, CLSA Limited, GF Securities (Hong Kong) Brokerage Limited |
TIME TABLE
| Application Period | May 15 (Thu) - noon, May 20 (Tue) |
| Price Determination Date | May 21 (Wed) |
| Result Announcement Date | On or before May 22 (Thu) |
| Result Announcement Date | On or before May 22 (Thu) |
| Result Announcement Date | On or before May 23 (Fri) |
| Dealings in Shares commence on | May 23, 2025. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 14X - 48X | 48X - 97X | Over 97X |
| % of total shares reallocated to HK Offer | 8.5% | 11.0% | 21.5% |
Sales Statistics (HKD)
| Offer Price | $41.45 - $44.05 |
| Capitalization (H Shares) | 93.10M - 98.90M |
| NAV / share ($) | $8.01 - $8.10 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 42.75, the net proceeds raised would be HKD 9.46B, of which |
| 75% : Allocated to R&D initiatives |
| 15% : Fund the construction of new production and R&D facilities in China and overseas markets, as well as the expansion or upgrade of existing production facilities in China. |
| 10% : Working capital |
IPO NEWS
| 23/05/2025 16:08 |
| {New Stock}HENGRUI PHARMA(01276) ends up 25.2% at HK$55.15 |
| 23/05/2025 09:20 |
| {New Stock}HENGRUI PHARMA(01276) opens up 29.4% at HK$57 |
| 22/05/2025 18:35 |
| {New Stock}HENGRUI PHARMA ends up 33.6% on grey market |
| 22/05/2025 16:20 |
| {New Stock}HENGRUI PHARMA up 27.13% at HK$56 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).